Niva Bupa Health Insurance Company Ltd

Rating Details

• Instrument: Subordinated debt (NCDs) proposed by Niva Bupa Health Insurance Company Limited.
• Size: ₹500 crore.
• Rating: IND AAA/Stable.
• Agency: India Ratings and Research Private Limited.
• Action: Rating assigned.
• Outlook: Stable.
• Issuance structure: Listed, rated, unsecured, subordinated, redeemable NCDs.
• Rationale: Not disclosed in the press release.
• Date: Oct 15, 2026.

Call option redemption

• Exercising call option to redeem 1,500 unsecured subordinated debentures aggregating ₹150 crore at par.
• Record date fixed at 02 Nov 2026; ISIN INE995S08010 to be frozen post-record date.
• Call Option Date: 15 Nov 2026; redemption payable on 13 Nov 2026 due to non-business day.
• Redemption price: ₹10,00,000 per debenture; total redemption ₹150 crore.
• IRDAI approval not required; solvency post-exercise to exceed 180%; IRDAI to be informed within 15 days.
• Trading suspended; ISIN frozen after record date; demat holders must ensure bank details are updated.
• Redemption to be paid to holders as on record date; otherwise by cheque/demand draft.
• On redemption, all debentures extinguished; no further principal or interest obligations.
• Outstanding principal for redemption remains ₹150 crore.

Niva Bupa Health Insurance Company Limited: Trading Window closed from Oct 01, 2026 till end of 48 hours after the Unaudited Financial Results for the quarter and half year ending on Sep 30, 2026 become generally available information.

Meeting Details

• Date and time: September 24, 2026 at 6:00 PM IST
• Type and mode: Institutional investor call; virtual
• Event: Sell-side & Buy-side institutional call
• Key participants: Company management
• Purpose: Institutional investor interaction

Rating details

• FSR: A-; ICR: a-; NSR: aaa.IN; Outlook: Stable.
• Balance sheet very strong with BCAR strongest as of FY2026.
• Operating performance adequate; four-year positive earnings, supported by robust investment returns.
• Underwriting improving due to lower expense ratio and expanded scale.
• Liquidity stable with access to capital markets for debt issuance.
• Bupa Group support and strategic importance underpin ratings.
• Market position: third in standalone health insurance with strong retail and digital capabilities.
• Rating enhancement reflects integration with and majority ownership by Bupa Group.

Cessation: Vikas Jain as CIO transitioning to CTO

• Vikas Jain ceases Chief Investment Officer role to become Chief Transformation Officer, effective 16 September 2026.
• Joined as CIO since October 2020; associated with the company since September 2015; remains Senior Management.
• Impact: transition to CTO; no other board/committee changes disclosed.

ESG rating disclosure

• Niva Bupa did not engage Niche99 ESG Ratings; rating assigned independently for FY 2024-25 and FY 2025-26.

Share Allotment Details

• Company allotted 4,11,000 equity shares on Aug 26, 2026; paid-up capital increased to ₹18,49,64,47,030 comprising 1,84,96,44,703 shares.
• ESOP 2020 allotted 1,92,100; ESOP 2024 allotted 2,18,900; ranking pari-passu.

Issuer Rating

• ICRA reaffirmed issuer rating at AAA(Stable) for Niva Bupa Health Insurance.
• Outlook: Stable for the issuer rating.
• Rating communicated on August 20, 2026.

Subordinated Debt Rating

• AA+(Stable) assigned to proposed subordinated debt up to ₹500 crore.
• Instrument: listed, rated, unsecured, subordinated NCDs.
• Rating valid for the life of the programme until withdrawn.
• ICRA reserves right to review or revise ratings at any time.
• Rating letters dated August 20, 2026.

EoM order and business impact

• IRDAI issued 19 Aug 2026 order warning for EoM non-compliance FY2024-25.
• Directive not to open new place of business for six months from order date.
• Company evaluating the order and will safeguard stakeholder interests.
• Company remains compliant with EoM Regulations 2024 for FY2026 and Q1 FY2026-27, on track for FY2027.
• Impact on financials reported as Nil.